A novel predictor for the use of concurrent chemotherapy in early-stage cervical cancer with intermediate-risk factors
Objective: For early-stage cervical cancer patients experiencing radical surgery, postoperative radiotherapy was recommended for patients with a combination of intermediate-risk factors. However, there was no consensus on whether to administer concurrent chemotherapy. The aim of the study was to con...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-08-01
|
| Series: | Gynecologic Oncology Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352578923000978 |
| _version_ | 1797753959422623744 |
|---|---|
| author | Chunli Fu Cong Wang Qiuhong Qian Youzhong Zhang Changdong Ma Li Miao Guangyu Zhang |
| author_facet | Chunli Fu Cong Wang Qiuhong Qian Youzhong Zhang Changdong Ma Li Miao Guangyu Zhang |
| author_sort | Chunli Fu |
| collection | DOAJ |
| description | Objective: For early-stage cervical cancer patients experiencing radical surgery, postoperative radiotherapy was recommended for patients with a combination of intermediate-risk factors. However, there was no consensus on whether to administer concurrent chemotherapy. The aim of the study was to confirm the clinical value of the controlling nutritional status (CONUT) score in guiding the use of concurrent chemotherapy during postoperative radiotherapy. Methods: A total of 969 patients with FIGO stage IB-IIA cervical cancer were retrospectively analyzed. Kaplan-Meier survival analysis was performed to compare disease-free survival (DFS) and cancer-specific survival (CSS) rates between different group. A Cox proportional hazards regression test was used to conduct multivariate analyses. Results: For the patients in the high CONUT group (≥3), the addition of concurrent chemotherapy had better 5-year DFS (91.2 % vs. 72.8 %, P = 0.005) and CSS (93.8 % vs. 77.4 %, P = 0.013) than those without it. Meanwhile, the patients with concurrent chemotherapy had less rate of locoregional recurrence (8.5 % vs 16.7 %, P = 0.034) and distant metastases (11.7 % vs 30.4 %, P = 0.015). The multivariate analysis showed that concurrent chemotherapy was detected to be a factor significantly associated with DFS (P = 0.011), local control (P = 0.041), distant metastasis (P = 0.005) and CSS (P = 0.023). For the patients in low CONUT group (<3), there was no difference in prognosis between patients. Conclusion: Pretreatment CONUT score may be a predictive factor for the use of concurrent chemotherapy in early-stage cervical cancer with intermediate-risk factors during postoperative radiotherapy, and it can be helpful to determine the adjuvant treatment scheme. |
| first_indexed | 2024-03-12T17:26:32Z |
| format | Article |
| id | doaj.art-6c0885bebfb74d1c82b965a1dda0247e |
| institution | Directory Open Access Journal |
| issn | 2352-5789 |
| language | English |
| last_indexed | 2024-03-12T17:26:32Z |
| publishDate | 2023-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Gynecologic Oncology Reports |
| spelling | doaj.art-6c0885bebfb74d1c82b965a1dda0247e2023-08-05T05:16:13ZengElsevierGynecologic Oncology Reports2352-57892023-08-0148101228A novel predictor for the use of concurrent chemotherapy in early-stage cervical cancer with intermediate-risk factorsChunli Fu0Cong Wang1Qiuhong Qian2Youzhong Zhang3Changdong Ma4Li Miao5Guangyu Zhang6Department of Geriatric Medicine, Qilu Hospital of Shandong University, Jinan, China; Key Laboratory of Cardiovascular Proteomics of Shandong Province, Qilu Hospital of Shandong University, Jinan, ChinaDepartment of Gynecology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, ChinaDepartment of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, ChinaDepartment of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, ChinaDepartment of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, ChinaDepartment of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, ChinaDepartment of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, China; Corresponding author at: Department of Radiation Oncology, Qilu Hospital of Shandong University, No 107 West Wenhua Road, Jinan 250012, Shandong Province, China.Objective: For early-stage cervical cancer patients experiencing radical surgery, postoperative radiotherapy was recommended for patients with a combination of intermediate-risk factors. However, there was no consensus on whether to administer concurrent chemotherapy. The aim of the study was to confirm the clinical value of the controlling nutritional status (CONUT) score in guiding the use of concurrent chemotherapy during postoperative radiotherapy. Methods: A total of 969 patients with FIGO stage IB-IIA cervical cancer were retrospectively analyzed. Kaplan-Meier survival analysis was performed to compare disease-free survival (DFS) and cancer-specific survival (CSS) rates between different group. A Cox proportional hazards regression test was used to conduct multivariate analyses. Results: For the patients in the high CONUT group (≥3), the addition of concurrent chemotherapy had better 5-year DFS (91.2 % vs. 72.8 %, P = 0.005) and CSS (93.8 % vs. 77.4 %, P = 0.013) than those without it. Meanwhile, the patients with concurrent chemotherapy had less rate of locoregional recurrence (8.5 % vs 16.7 %, P = 0.034) and distant metastases (11.7 % vs 30.4 %, P = 0.015). The multivariate analysis showed that concurrent chemotherapy was detected to be a factor significantly associated with DFS (P = 0.011), local control (P = 0.041), distant metastasis (P = 0.005) and CSS (P = 0.023). For the patients in low CONUT group (<3), there was no difference in prognosis between patients. Conclusion: Pretreatment CONUT score may be a predictive factor for the use of concurrent chemotherapy in early-stage cervical cancer with intermediate-risk factors during postoperative radiotherapy, and it can be helpful to determine the adjuvant treatment scheme.http://www.sciencedirect.com/science/article/pii/S2352578923000978Cervical CancerRadiotherapyConcurrent ChemotherapyCOUNT Score |
| spellingShingle | Chunli Fu Cong Wang Qiuhong Qian Youzhong Zhang Changdong Ma Li Miao Guangyu Zhang A novel predictor for the use of concurrent chemotherapy in early-stage cervical cancer with intermediate-risk factors Gynecologic Oncology Reports Cervical Cancer Radiotherapy Concurrent Chemotherapy COUNT Score |
| title | A novel predictor for the use of concurrent chemotherapy in early-stage cervical cancer with intermediate-risk factors |
| title_full | A novel predictor for the use of concurrent chemotherapy in early-stage cervical cancer with intermediate-risk factors |
| title_fullStr | A novel predictor for the use of concurrent chemotherapy in early-stage cervical cancer with intermediate-risk factors |
| title_full_unstemmed | A novel predictor for the use of concurrent chemotherapy in early-stage cervical cancer with intermediate-risk factors |
| title_short | A novel predictor for the use of concurrent chemotherapy in early-stage cervical cancer with intermediate-risk factors |
| title_sort | novel predictor for the use of concurrent chemotherapy in early stage cervical cancer with intermediate risk factors |
| topic | Cervical Cancer Radiotherapy Concurrent Chemotherapy COUNT Score |
| url | http://www.sciencedirect.com/science/article/pii/S2352578923000978 |
| work_keys_str_mv | AT chunlifu anovelpredictorfortheuseofconcurrentchemotherapyinearlystagecervicalcancerwithintermediateriskfactors AT congwang anovelpredictorfortheuseofconcurrentchemotherapyinearlystagecervicalcancerwithintermediateriskfactors AT qiuhongqian anovelpredictorfortheuseofconcurrentchemotherapyinearlystagecervicalcancerwithintermediateriskfactors AT youzhongzhang anovelpredictorfortheuseofconcurrentchemotherapyinearlystagecervicalcancerwithintermediateriskfactors AT changdongma anovelpredictorfortheuseofconcurrentchemotherapyinearlystagecervicalcancerwithintermediateriskfactors AT limiao anovelpredictorfortheuseofconcurrentchemotherapyinearlystagecervicalcancerwithintermediateriskfactors AT guangyuzhang anovelpredictorfortheuseofconcurrentchemotherapyinearlystagecervicalcancerwithintermediateriskfactors AT chunlifu novelpredictorfortheuseofconcurrentchemotherapyinearlystagecervicalcancerwithintermediateriskfactors AT congwang novelpredictorfortheuseofconcurrentchemotherapyinearlystagecervicalcancerwithintermediateriskfactors AT qiuhongqian novelpredictorfortheuseofconcurrentchemotherapyinearlystagecervicalcancerwithintermediateriskfactors AT youzhongzhang novelpredictorfortheuseofconcurrentchemotherapyinearlystagecervicalcancerwithintermediateriskfactors AT changdongma novelpredictorfortheuseofconcurrentchemotherapyinearlystagecervicalcancerwithintermediateriskfactors AT limiao novelpredictorfortheuseofconcurrentchemotherapyinearlystagecervicalcancerwithintermediateriskfactors AT guangyuzhang novelpredictorfortheuseofconcurrentchemotherapyinearlystagecervicalcancerwithintermediateriskfactors |